腺病毒血清型 26 利用 CD46 作为主要细胞受体，在恒河猴接种后仅短暂激活 T 淋巴细胞。
Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys.
机构信息
Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
出版信息
J Virol. 2012 Oct;86(19):10862-5. doi: 10.1128/JVI.00928-12. Epub 2012 Jul 18.
Abstract
The cellular receptor utilized by adenovirus serotype 26 (Ad26) has remained unclear. Here we show that Ad26 transduction is CD46-dependent and is efficiently blocked by anti-CD46 but not anti-CAR antibodies, demonstrating that Ad26 utilizes CD46 as a primary cellular receptor. Moreover, following Ad26 vaccination of rhesus monkeys, we did not observe sustained activation of peripheral or mucosal vector-specific CD4(+) T lymphocytes. These data contribute to our understanding of Ad26 as a candidate vaccine vector.
摘要
腺病毒血清型 26（Ad26）所利用的细胞受体仍不清楚。在这里，我们表明 Ad26 的转导依赖于 CD46，并且可以被抗 CD46 但不是抗 CAR 抗体有效阻断，这表明 Ad26 将 CD46 用作主要的细胞受体。此外，在恒河猴接种 Ad26 疫苗后，我们没有观察到外周或粘膜载体特异性 CD4(+)T 淋巴细胞的持续激活。这些数据有助于我们了解 Ad26 作为候选疫苗载体。
相似文献
1
Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys.腺病毒血清型 26 利用 CD46 作为主要细胞受体，在恒河猴接种后仅短暂激活 T 淋巴细胞。
J Virol. 2012 Oct;86(19):10862-5. doi: 10.1128/JVI.00928-12. Epub 2012 Jul 18.
2
and CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26).并且物种 D 型人腺病毒血清型 26（HAdV26）对 CD46 受体的利用。
J Virol. 2022 Feb 9;96(3):e0082621. doi: 10.1128/JVI.00826-21. Epub 2021 Nov 17.
3
Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys.接种腺病毒血清型 35、26 和 48 比接种血清型 5 能在恒河猴中引起更高水平的先天细胞因子反应。
J Virol. 2012 Sep;86(18):9590-8. doi: 10.1128/JVI.00740-12. Epub 2012 Jul 11.
4
Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation.腺病毒 35 型载体通过与 CD46 的结合阻断人 CD4+T 细胞的激活。
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7499-504. doi: 10.1073/pnas.1017146108. Epub 2011 Apr 18.
5
Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer.靶向 CD46 增强腺病毒 5 型对膀胱癌的抗肿瘤活性。
Int J Mol Sci. 2018 Sep 10;19(9):2694. doi: 10.3390/ijms19092694.
6
Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions.腺病毒纤维扣超变环内的多样性影响主要受体相互作用。
Nat Commun. 2019 Feb 14;10(1):741. doi: 10.1038/s41467-019-08599-y.
7
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).在一项多中心、随机、双盲、安慰剂对照的 1/2a 期临床试验（APPROACH）和恒河猴（NHP 13-19）中评估马赛克 HIV-1 疫苗。
Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.
8
Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination.用于疫苗接种的含35型纤维的腺病毒载体评估。
Mol Ther. 2006 Apr;13(4):756-65. doi: 10.1016/j.ymthe.2005.12.008. Epub 2006 Feb 7.
9
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys.在感染猴免疫缺陷病毒（SIV）的恒河猴中进行的携带Toll样受体7（TLR7）刺激的腺病毒26型/改良痘苗病毒安卡拉（Ad26/MVA）治疗性疫苗接种。
Nature. 2016 Dec 8;540(7632):284-287. doi: 10.1038/nature20583. Epub 2016 Nov 9.
10
Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys.重组腺病毒疫苗在恒河猴中诱导的全身和黏膜T淋巴细胞激活
J Virol. 2009 Oct;83(20):10596-604. doi: 10.1128/JVI.01170-09. Epub 2009 Aug 5.
引用本文的文献
1
Early spatiotemporal evolution of the immune response elicited by adenovirus serotype 26 vector vaccination in mice.26型腺病毒载体疫苗接种小鼠后引发的免疫反应的早期时空演变
J Virol. 2025 May 20;99(5):e0024725. doi: 10.1128/jvi.00247-25. Epub 2025 Mar 31.
2
Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses.经肌肉内注射基于腺病毒 26 的载体疫苗免疫小鼠后，峰值转基因表达与转基因特异性适应性免疫应答相关。
PLoS One. 2024 Apr 16;19(4):e0299215. doi: 10.1371/journal.pone.0299215. eCollection 2024.
3
COVID-19 vaccines adverse events: potential molecular mechanisms.新型冠状病毒肺炎疫苗不良反应：潜在的分子机制。
Immunol Res. 2023 Jun;71(3):356-372. doi: 10.1007/s12026-023-09357-5. Epub 2023 Jan 6.
4
SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders.SARS-CoV-2 疫苗：类型、作用原理及其对血栓和胃肠道紊乱的影响。
Appl Biochem Biotechnol. 2023 Feb;195(2):1541-1573. doi: 10.1007/s12010-022-04181-3. Epub 2022 Oct 12.
5
Human Adenovirus Type 26 Infection Mediated by αvβ3 Integrin Is Caveolin-1-Dependent.人腺病毒 26 型通过αvβ3 整合素感染是窖蛋白-1 依赖性的。
Microbiol Spectr. 2022 Aug 31;10(4):e0109722. doi: 10.1128/spectrum.01097-22. Epub 2022 Aug 4.
6
Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines.SARS-CoV-2 免疫反应与 COVID-19 疫苗的关系研究进展。
J Microbiol. 2022 Mar;60(3):308-320. doi: 10.1007/s12275-022-1598-x. Epub 2022 Mar 2.
7
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization.异源系统初级-黏膜加强免疫后对 SARS-CoV-2 的保护性黏膜免疫。
Nat Commun. 2021 Nov 26;12(1):6871. doi: 10.1038/s41467-021-27063-4.
8
Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination.对腺病毒载体 COVID-19 疫苗接种后血小板减少症和血栓形成的不良反应的担忧。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211040110. doi: 10.1177/10760296211040110.
9
COVID-19 Vaccines and Thrombosis-Roadblock or Dead-End Street?COVID-19 疫苗与血栓：路障还是死胡同？
Biomolecules. 2021 Jul 13;11(7):1020. doi: 10.3390/biom11071020.
10
To clot or not to clot? Ad is the question-Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia.是否形成血栓？这是一个问题——疫苗诱导的血栓性血小板减少症相关机制的见解。
J Thromb Haemost. 2021 Nov;19(11):2845-2856. doi: 10.1111/jth.15485. Epub 2021 Aug 23.
本文引用的文献
1
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.儿童和成人人群中腺病毒血清型 5、26、35 和 48 的国际血清流行病学研究。
Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25.
2
Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.腺病毒载体疫苗：三种腺病毒科病毒载体的比较。
J Virol. 2010 Oct;84(20):10522-32. doi: 10.1128/JVI.00450-10. Epub 2010 Aug 4.
3
Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5.黏膜途径中载体特异性 CD4+T 淋巴细胞在恒河猴接种腺病毒血清型 5 后的迁移。
J Virol. 2010 Oct;84(19):9810-6. doi: 10.1128/JVI.01157-10. Epub 2010 Aug 4.
4
Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration.上调 CD59：保护神经元免受补体介导的退化的新策略。
Pharmacogenomics J. 2010 Feb;10(1):12-9. doi: 10.1038/tpj.2009.52. Epub 2009 Nov 3.
5
Adenovirus receptors: implications for tropism, treatment and targeting.腺病毒受体：对嗜性、治疗和靶向作用的影响
Rev Med Virol. 2009 May;19(3):165-78. doi: 10.1002/rmv.612.
6
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.一种细胞介导免疫HIV-1疫苗的疗效评估（STEP研究）：一项双盲、随机、安慰剂对照的概念验证试验。
Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.
7
Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.重组腺病毒载体和异源初免-加强免疫方案在恒河猴中引发的细胞免疫反应的强度和表型。
J Virol. 2008 May;82(10):4844-52. doi: 10.1128/JVI.02616-07. Epub 2008 Mar 12.
8
Adenovirus serotype 5 hexon mediates liver gene transfer.腺病毒5型六邻体介导肝脏基因转移。
Cell. 2008 Feb 8;132(3):397-409. doi: 10.1016/j.cell.2008.01.016.
9
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.来自B和D亚组的六种罕见血清型重组腺病毒疫苗载体的比较血清阳性率和免疫原性。
J Virol. 2007 May;81(9):4654-63. doi: 10.1128/JVI.02696-06. Epub 2007 Feb 28.
10
CD46 is a cellular receptor for group B adenoviruses.CD46是B组腺病毒的细胞受体。
Nat Med. 2003 Nov;9(11):1408-12. doi: 10.1038/nm952. Epub 2003 Oct 19.
Zotero 插件